The second strategic cooperation with Eli Lilly has jointly developed the sodium glucose co transporter (SGLT1) molecule for the treatment of diabetes.

Asia Pharmaceutical (Shanghai Securities: 600351) announced the second strategic cooperation with Eli Lilly on diabetes treatment in October 20, 2015 to jointly promote the sodium glucose co transporter (SGLT1) molecule developed by Lilly. Lilly's SGLT1 inhibitor project has completed phase I clinical trials in Singapore and has rich preclinical data. In July 2014, Lilly and Yabao announced the joint development of Lilly's glucokinase activator (GKA), ly2608204.
There are huge gaps in the treatment of diabetes all over the world. Because SGLT1 acts independently on β SGLT1 suppression in cells is a promising treatment for early and late diabetes. The decrease of blood glucose and insulin can improve the metabolic state and function β The cells are healthy and will not cause the side effects of weight gain and hypoglycemia. When sharing other important diabetes drugs, its complementary mechanism is an effective way to treat diabetes.
According to the terms of the agreement, Yabao pharmaceutical obtained the right to develop and sell SGLT1 compound in China, while Lilly reserved other market rights. The two sides will work together to determine China's strategic development plan. Yabao pharmaceutical will first be responsible for implementing and financing all development. Lilly reserves the call option on the future Chinese market. The financial terms have not been disclosed.
Dr. Wang Peng, R & D president of Yabao company, said: "Lilly company has gained the SGLT1 inhibitor from the understanding of the mechanism of action, and has been through the chemical route. The inhibitor may become a market drug." Ai Bao is pleased to cooperate with Lilly company again. This is our second strategic cooperation, and our common commitment to China's diabetes patients. This cooperation is the technology used by the pharmaceutical company to treat major diseases. Another example. "
About Yabao pharmaceutical
Yabao Pharmaceutical (Shanghai Securities 600351) As a Chinese pharmaceutical enterprise, Yabao has perfect capabilities in drug development, production and commercialization in China. Recently, Yabao has adjusted its strategic development direction and aimed at the field of innovative drugs in addition to its mature cause in the field of modern Chinese traditional medicine and chemical generic drugs. Yabao has strong clinical and regulatory capabilities, and the production of preparations and APIs meets the quality management of drug production CGMP requirements and passed the inspection of FDA and EU drug regulatory authorities respectively.

Next:SY-008, a diabetes candidate drug developed jointly with Eli Lilly, is being applied again in China.